Special Issue "New Frontiers in Treatment of Pancreatic Cancer"
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".
Deadline for manuscript submissions: 15 January 2024 | Viewed by 13998
Special Issue Editors
Interests: pancreatic cancer; hepatobilary cancer; phase II/III trials; symptom mangement; cancer cachexia; patient reported outcomes
Interests: pancreatic cancer; clinical trials; biomarkers
Interests: pancreatic cancer; clinical trials; pathology
Special Issue Information
Dear Colleagues,
Pancreatic cancer remains a challenging clinical problem. It is foreseen that the disease will become the second cause of cancer deaths in the western world. To avoid this epidemic, progress will be needed through multiple approaches. In this Special Edition, we therefore welcome original papers and reviews in the following fields of pancreatic cancer research: improved prevention and early diagnostic strategies, molecular tumor stratification for personalized and molecularly targeted antitumor treatment, and the development of rational and tolerable multimodal therapies in the neoadjuvant, adjuvant, and palliative setting, also including radiotherapy.
In addition to tumor-directed treatment, there is a great need to improve quality of life in patients with pancreatic cancer through better symptom control, such as pain management, treatment of cachexia, and psychosocial support, and we also encourage the submission of papers focusing on these.
Dr. Olav F. Dajani
Dr. Knut Jørgen Labori
Dr. Arne Westgaard
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer (adenocarcinoma)
- chemotherapy
- immunotherapy
- radiotherapy
- personalized medicine
- predictive biomarkers
- prognostic biomarkers
- symptom management
- cachexia
- pain management
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
rd
Guest Editors